Indications and Usage
RESTASIS^® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Important Safety Information
Contraindications
RESTASIS^® is contraindicated in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.

Warnings and Precautions
Potential for Eye Injury and Contamination
To avoid the potential for eye injury and contamination, individuals prescribed RESTASIS^® should not touch the vial tip to their eye or other surfaces.

Use With Contact Lenses
RESTASIS^® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion. Lenses may be reinserted 15 minutes following administration of RESTASIS^® Ophthalmic Emulsion.

Adverse Reactions
In clinical trials, the most common adverse reaction following the use of cyclosporine ophthalmic emulsion 0.05% was ocular burning (upon instillation)—17%. Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most ofen blurring).

Click here for full Product Information for RESTASIS^®.

This promotional event is brought to you by Allergan, an AbbVie company, and is not certified for continuing medical education.
The speaker is a paid consultant presenting on the behalf of Allergan and the information being presented is consistent with FDA guidelines.
This event is conducted in accordance with industry guidelines on Interactions with Healthcare Professionals and is limited to invited healthcare professionals (HCPs).